A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...

The Bangladesh Securities and Exchange Commission (BSEC) yesterday approved the issuance of subordinated bonds totalling Tk2,000 crore by five banks to strengthen their Tier-2 capital base. All the ...

When equity investors are struggling amid the inflationary cycle, smart investors continue to rush into fixed income for the third consecutive year. Bangladesh's equity-focused mutual fund industry ...

Bitcoin has kept refreshing all-time highs over the past few days, leading to increased investors’ interests but also ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

At Fleet Week in San Diego, fleet professionals gathered to learn — and themselves formulate — the industry’s next steps in ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...